Global Lenalidomide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Lenalidomide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.
Lenalidomide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Lenalidomide market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Multiple myeloma (MM) and Myelodysplastic syndromes (MDS) are the major drivers for the industry.
In China, Lenalidomide key players include Celgene, SL Pharma.
In terms of product, 25 mg Capsules is the largest segment, with a share over 40%. And in terms of application, the largest application is Multiple myeloma (MM), followed by Myelodysplastic syndromes (MDS).
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Lenalidomide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Celgene
SL Pharma
Segment by Type
5 mg Capsules
10 mg Capsules
15 mg Capsules
25 mg Capsules
Multiple myeloma (MM)
Myelodysplastic syndromes (MDS)
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Lenalidomide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Lenalidomide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Lenalidomide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Lenalidomide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Lenalidomide introduction, etc. Lenalidomide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Lenalidomide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Lenalidomide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Lenalidomide market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Multiple myeloma (MM) and Myelodysplastic syndromes (MDS) are the major drivers for the industry.
In China, Lenalidomide key players include Celgene, SL Pharma.
In terms of product, 25 mg Capsules is the largest segment, with a share over 40%. And in terms of application, the largest application is Multiple myeloma (MM), followed by Myelodysplastic syndromes (MDS).
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Lenalidomide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Celgene
SL Pharma
Segment by Type
5 mg Capsules
10 mg Capsules
15 mg Capsules
25 mg Capsules
Segment by Application
Multiple myeloma (MM)
Myelodysplastic syndromes (MDS)
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Lenalidomide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Lenalidomide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Lenalidomide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Lenalidomide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Lenalidomide introduction, etc. Lenalidomide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Lenalidomide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices